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Introduction: Depression is considered an independent risk factor for hypertension, particularly 
for people with recurrent episodes or a long history of depression. Another risk factor for car-
diovascular disease is the Apolipoprotein E e4 allele (ApoE e4). The aim of this study was to 
examine how ApoE e4 was related to blood pressure (BP) in patients with depression and a 
control group.
Methods: A total of 78 patients, 49 with depression and 29 without, all recruited from the same 
hospital, underwent ApoE e genotyping (24 had at least one ApoE e4 allele) and examination 
of BP.
Results: In the depression group, but not in the control group, both systolic and diastolic BP 
were significantly higher in patients with ApoE e4 than in those without. The effect of ApoE 
e4 on BP differed significantly between the two groups.
Conclusion: Our findings showed that the effect of ApoE e4 on BP differed between the patients 
with depression and the control group. In patients with depression, ApoE e4 was associated 
with an increase in BP. We suggest that patients with depression and ApoE e4-positive status 
are particularly prone to develop BP elevation.
Keywords: depression, blood pressure, ApoE e4, ApoE, genotyping
Introduction
The literature suggests that blood pressure (BP) alterations are associated with 
psychopathology, especially depression.1–4 Nonetheless, the reported relationship 
between depression and BP alteration is inconsistent. Depression has been considered 
an independent risk factor for hypertension, particularly for people with recurrent 
episodes or a long-term history of depression.5 Yet most studies report that depression 
is related to lower rather than higher BP.4,6 Two longitudinal studies have shown that 
high levels of anxiety and depression at baseline, with an increase in these symptoms 
over time, were associated with lower systolic BP in an 11-year follow-up study.7,8
Depression has been associated with a high rate of cardiovascular diseases.9–11 
In an 8-year follow-up study, an increased risk of stroke or transient ischemic attacks 
was observed in depressed patients younger than 65 years, but not among those over 
65.12 In a meta-analysis, the most prominent risk factor for cardiovascular diseases 
was found to be depression.13 It is possible, therefore, that depression may influence 
factors related to cerebrovascular disorders, such as hypertension.
The human Apolipoprotein E (ApoE) has three allelic variants, e2, e3, and e4, 
encoded on chromosome 19. A person could be homozygotic, with two e4 alleles (one 
from each parent); or heterozygotic, with one e4 allele in combination with either an 
e2 or an e3 allele. The heterozygotic e4 variant, found in approximately 18% of the 
Norwegian population,14 has been associated with atherosclerosis, Alzheimer’s  disease, 
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general impaired cognitive function, and reduced hippocam-
pal volume.15–19
Little is known about the association between depression 
and ApoE e4, but some studies have reported the e4 allele 
to be a risk factor.19–21 All the research we have been able to 
find has examined this association in older people, often in 
patients with cognitive deficits or dementia.22
The research question in this study was: “Is the ApoE 
e4 allele in persons with depression associated with systolic 
and diastolic BP?” At the same time, we wanted to examine 
a control group of patients without known depression or 
diagnosed disease who had presented with diffuse neurologi-
cal symptoms such as tiredness or vague symptoms like their 
body not functioning as it should.
Materials and methods
Patients and controls
A group of 49 depressed patients were recruited from inpa-
tient wards and outpatient clinics of the mental health unit 
at Innlandet Hospital Trust, Norway. They were all over 18 
years of age and had been diagnosed with depression (Inter-
national Statistical Classification of Diseases and Related 
Health Problems, tenth revision [ICD-10]; F32–34 spectre). 
The control group comprised 29 patients over 18 years of 
age, referred to the Department of Neurology at the same 
hospital for diffuse symptoms for which no disease could be 
diagnosed. They were included after exclusion of organic 
disorders. None of the depressed patients or the controls 
showed any signs of neurological disease.
examinations and assessments
A medical history was recorded, a routine clinical examina-
tion was performed, and hematological and biochemical 
screening tests were carried out in all participants. The 
cerebrospinal fluid of all participants was examined. The 
first author confirmed the clinical diagnoses of depres-
sion after careful patient examinations using the ICD-10 
criteria for research, which revealed mild-to-severe symp-
toms of depression (F32–34). A neurologist conducted a 
detailed examination of the patients in the Department 
of Neurology, and only those with no clinical or labora-
tory indication of a neurological diagnosis or depression 
were included. No cerebral neuropathology was found 
in any depressed patients or patients with neurological 
symptoms, based upon clinical examination, cerebrospinal 
fluid examination, or computed tomography or magnetic 
resonance imaging (the computed tomography or mag-
netic resonance imaging for the control group and in the 
depression group if there were any indication or suspicion 
of cerebral disorder).
genotyping
The whole-blood samples were collected by a bioengineer 
using EDTA glass vacutainers and sent to the Depart-
ment of Medical Biochemistry, Oslo University Hospital, 
Rikshospitalet, Norway, for ApoE e analysis. Genotyping was 
performed by real-time polymerase chain reaction with allele-
specific fluorescence energy transfer probes and melting curve 
analysis on the LightCycler system (Roche Diagnostics, Basel, 
Switzerland). DNA was extracted from 300 µL of whole blood 
using MagNA Pure LC DNA Isolation Kit – Large Volume on 
the MagNA Pure LC (Roche Diagnostics), eluted and diluted 
to 1 mL, of which 5 µL was used in each assay. Genotyping of 
the ApoE e2, e3, and e4 was performed using the LightCycler 
ApoE Mutation Detection Kit (Roche Diagnostics). The assay 
was performed as specified by the supplier, except for scaling 
down the total assay volume from 20 µL to 10 µL. The labo-
ratory participates in an external quality assurance program 
(Equalis) that includes ApoE genotyping.
The Beck Depression Inventory-II (BDI-II)23 was used 
as an indicator of depression severity.
A digital Microlife BP 3 AGI apparatus (Microlife 
AG Swiss Corporation, Widnau, Switzerland) was used 
to record BP, following the standard procedure delineated 
in the manual. (See user manual home page: http://www.
microlife.com/products/hypertension/automatic/bp-3ag1) 
According to ICD-10, a BP of 120/80 mmHg (systolic/
diastolic) or lower is normal BP. A pressure 140/90 mmHg 
or higher is regarded as high BP. Systolic pressure between 
120 mmHg and 139 mmHg, or diastolic between 80 mmHg 
and 89 mmHg is regarded as prehypertension.
ethics
The study was reviewed and approved by the Regional 
Committees for Medical and Health Research Ethics, South 
East A, Reference no 2009/2196a, and all participants 
provided written informed consent form before they were 
included in the study.
statistics
Independent samples t-test or chi-square analyses were per-
formed in the two groups to test the presence/absence of ApoE 
e4, BP, age, sex, and antihypertensive medication. Univariate 
analysis of variance with and without the interaction between 
groups (control vs depression) and presence or absence of 
ApoE e4 was used to study predictors of BP. Age, sex, and 
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antihypertensive medication were included as covariates. SPSS 
Version 22 (IBM Corporation, Armonk, NY, USA) was used 
for the analyses. Finally, the same analyses were performed 
without the participants who were on antihypertensive drugs.
Results
Table 1 lists characteristics of patients in the two groups. 
Only the score on BDI-II differed between the two groups. 
Many of the patients in both groups said they had more fatigue 
than before: 24 out of 29 in the control group and 45 out of 49 in 
the depression group. The typical symptom in the control group 
was fatigue. Apart from that, seven struggled with headache, 
six had some muscle pain or numbness or tendencies for tremor 
in arms or legs, three had some form of dizziness, one had a 
tendency to ataxia, and one patient had reported optic neuritis. 
Patients could have one or more of these symptoms.
In the control group, there was one participant with 2/3 
allele combination, 15 with 3/3, 12 with 3/4, and one with 
4/4. In the depression group, three had 2/3, 29 had 3/3, 15 
had 3/4, and two had 4/4 allele combination.
Table 2 lists systolic and diastolic BP (mmHg), age, sex, 
and antihypertensive medication in patients with and without 
ApoE e4, with separate analysis for the depressed and the 
control group. As listed in Table 2, the BP analyses were also 
performed excluding the subjects on antihypertensive drugs, 
showing no significant differences in results.
Both systolic and diastolic BP were significantly higher 
among the depressed ApoE e4 allele group as compared to 
Table 1 Characteristics of the two groups: mean (SD), number of participants (%), and significance testing
Participant characteristics Depression,  
n=49
Neurological symptoms  
(controls), n=29
Statistics  
(P-value)
Females (%) 26 (53.1%) 20 (69.0%) Ns (P=0.17)
age, years 45.3 (14.6) 43.45 (13.51) Ns (P=0.58)
apoe e4 present 17 (34.7%) 13 (44.8%) Ns (P=0.37)
systolic BP, mmhg 128.35 (20.0) 129.96 (22.0) Ns (P=0.73)
Diastolic BP, mmhg 78.96 (12.79) 81.76 (13.78) Ns (P=0.37)
Use of antihypertensive drugs 9 (18.4%) 5 (17.2%) Ns (P=0.90)
BDi-ii 30.1 (12.4) 7.14 (6.87) P,0.000001
Notes: sex, apoe e4, and use of antihypertensive drugs, analyzed by chi-squared analysis. For the other variables, student’s t-tests were used.
Abbreviations: ApoE e4, Apolipoprotein E e4 allele; BP, blood pressure; BDI-II, Beck Depression Inventory-II; SD, standard deviation; NS, not significant.
Table 2 The control and depression groups divided according to if the apoe e4 allele was present or not
Groups ApoE e4  
present
ApoE e4  
absent
Statistics 
(P-value)
Depression n=17 n=32
all patients
systolic BP, mmhg 142.4 (19.7) 120.9 (15.1) 0.0001
Diastolic BP, mmhg 87.3 (11.1) 75.5 (11.4) 0.0005
age, years 43.2 (14.9) 49.2 (13.5) 0.18
sex (females/males) 5/12 21/11 0.02
antihypertensive drugs n=7 n=6 0.17
Patients not using antihypertensive drugs n=10 n=26
systolic BP, mmhg 141.4 (21.0) 120.8 (13.6) 0.001
Diastolic BP, mmhg 85.8 (11.5) 74.0 (10.4) 0.005
Neurological symptoms (controls) n=13 n=16
all patients
systolic BP, mmhg 123.7 (10.4) 135.1 (24.7) 0.13
Diastolic BP, mmhg 79.5 (10.2) 83.6 (16.2) 0.43
age, years 42.0 (9.4) 45.2 (15.7) 0.47
sex (females/males) 10/3 12/6 0.70
antihypertensive drugs n=1 n=4 0.40
Patients not using antihypertensive drugs n=12 n=12
systolic BP, mmhg 123.8 (10.9) 124.8 (11.0) 0.81
Diastolic BP, mmhg 79.5 (10.7) 76.8 (9.3) 0.52
Notes: Values are given as mean (sD) for systolic and diastolic BP and age. student’s t-test and chi-square analysis were performed.
Abbreviations: apoe e4, apolipoprotein e e4 allele; BP, blood pressure; sD, standard deviation.
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Table 4 The interaction between group (depressed/not depressed) and apoe e (e4 or not) regarding systolic and diastolic BP
Systolic BP (all 
patients) B (95% CI); 
P-value
Diastolic BP (all 
patients) B (95% CI); 
P-value
Systolic BP (patients not 
using antihypertensive 
drugs) B (95% CI); P-value
Diastolic BP (patients not 
using antihypertensive 
drugs) B (95% CI); P-value
interaction group/apoe e4 26.7 (10.0:43.4); P=0.002 12.4 (0.6:24.2); P=0.04 20.6 (5.3:35.9); P=0.009 8.8 (-3.0:20.6); P=0.1
Notes: The analysis was first done for all participants (first two columns). In the last two columns, those on antihypertensive drugs were excluded. Univariate analysis of 
variance with the interaction between groups (control or depression) and apoe e4 (presence or absence).
Abbreviations: ApoE e4, Apolipoprotein E e4 allele; BP, blood pressure; CI, confidence interval.
Table 3 Test of between-subjects effects
Dependent variables Covariates
Group  
(neuro/depressed)
ApoE e4  
(absent/present)
Sex (f/m) Age (years) Antihypertensive 
treatment (no/yes)
B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value B (95% CI) P-value
systolic BP (all patients) -3.17 
(-11.6:5.3)
0.46 6.1 
(-2.2:14.4)
0.15 5.2 
(-3.2:13.6)
0.22 0.5 (0.2:0.8) 0.004 4.8 
(-6.3:15.9)
0.39
Diastolic BP (all patients) -3.77 
(-9.5:2.0)
0.20 4.67 
(-1.0:10.4)
0.11 3.0 
(-0.2:7.8.7)
0.30 0.20 
(-0.03:0.43)
0.08 6.4 
(-1.2:14.0)
0.10
systolic BP (patients not 
using antihypertensive drugs)
3.80 
(-4.1:11.7)
0.34 9.68 
(1.7:17.6)
0.02 5.7 
(-2.1:13.5)
0.15 0.31 
(0.01:0.60)
0.04
Diastolic BP (patients not 
using antihypertensive drugs)
0.48 
(-5.3:6.3)
0.87 7.29 
(1.41:13.2)
0.02 2.1 
(-3.7:7.9)
0.46 0.11 
(10.1:0.3)
0.33
Notes: Univariate ANOVA was performed with a significance level set to 0.05. Dependent variables were systolic and diastolic BP (in mmHg); independent variables (fixed 
factors) were grouped (depression vs controls) and possessing at least one apoe e4 allele (yes vs no). covariates were age, sex, and antihypertensive medication. The analyses 
were redone after excluding those on antihypertensive drugs (the last two rows in the table).
Abbreviations: ApoE e4, Apolipoprotein E e4 allele; BP, blood pressure; CI, confidence interval.
the depressed non-ApoE e4 group. The nondepressed group 
demonstrated no such differences.
Univariate analyses of variance were then performed, 
with systolic and diastolic BP as the dependent variables; 
with group (control vs depression) and ApoE e4 (yes or no) 
as independent variables; and age, sex, and antihyperten-
sive medications as covariates. The results are listed in 
Table 3.
A main effect was seen for age relative to systolic BP for 
all participants, which was still there after excluding those 
on antihypertensive drugs. When those on antihypertensive 
drugs were excluded, a main effect was also seen for ApoE 
e allele for both systolic and diastolic BP.
The interaction between group (depressed/not depressed) 
and ApoE e (e4 or not) regarding BP is listed in Table 4.
The interaction between group and ApoE e was highly sig-
nificant (F=10.18, P=0.002 for systolic BP), with a moderate 
close to high eta2 (0.13). The estimated marginal means for 
the systolic and diastolic BP are shown in Figure 1.
Discussion
We found a clear interaction between depression and 
ApoE e4 regarding BP, especially for systolic, but also 
for diastolic pressure. The combination of ApoE e4 and 
depression resulted in a 21.5 mmHg difference in systolic 
BP between patients with and without the ApoE e4 in the 
depression group. Thus, our findings indicate that there is 
a tendency for higher BP in depressed patients carrying 
an ApoE e4 allele compared to depressed patients with 
no such gene. The same tendencies could be seen for 
diastolic as for systolic BP, although the tendency was 
slightly weaker.
Earlier studies regarding depression and BP have been 
inconclusive, showing not only that hypertension was related 
to depression,5 but also that depressed patients exhibited 
lower levels of BP than did healthy control subjects.4,6 As for 
our study, where no ApoE e4 is present, there is a tendency for 
lower levels of BP in the depressed group than among controls 
(Table 1 and Figure 1). The interaction between ApoE e4 and 
depression became weaker, especially for diastolic BP, when 
those on antihypertensive medication were excluded. This 
effect was probably due to the lower n in the last analyses. 
It could be that the two previous studies showing low levels 
of BP in depressed patients had included fewer patients with 
an ApoE e4 allele than were included in our study. Neither 
of those studies examined ApoE genotypes.
The ApoE e4 allele was initially recognized for its 
importance in lipoprotein metabolism and cardiovascular 
disease, such as atherosclerosis, and related cerebrovascular 
disease.24,25 Research has shown depression to be associated 
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Figure 1 estimated marginal means where the dependent variable was systolic and diastolic BP in all patients and in patients without antihypertensive treatment.
Notes: apoe e4 (yes/no) and the two groups (depression vs controls), age, sex, use of antihypertensive medication, and the interaction between group and apoe e4 were 
covariates.
Abbreviations: apoe e4, apolipoprotein e e4 allele; BP, blood pressure.
with systemic immune activation and inflammation, 
endothelial dysfunction, and increased cardiovascular mor-
bidity and mortality. Depression and cardiovascular disease 
are interrelated: depression predicts cardiovascular disease 
onset and adverse outcome in patients with known cardiovas-
cular disease.26 The combination of depression and ApoE e4 
seems to be related to elevated BP, which may then be 
associated with cardiovascular disease. There are probably 
different interacting relationships between ApoE e4 and 
depression. On the background of the difficulties described in 
association with ApoE e4, it is likely that this allele is some 
type of vulnerability gene, which put the person with that 
gene at risk for several diseases and disorders. It has also been 
repeatedly seen that ApoE e4 is a risk factor for dementia. 
Likewise, depression may be the first symptom of or a risk 
factor for dementia in old age. We suggest that the driving 
force is ApoE e4’s influence on BP and that biology (ApoE 
e4) and psychology (depression) are closely interwoven in 
the elevation of BP.
The proportion of persons with an ApoE e4-positive status 
in this sample of patients with depression and neurological 
symptoms was higher than that found in a representative 
sample of the general Norwegian population based in 
the same catchment area:27 38% vs 18.2%. Furthermore, no 
significant difference existed between the two groups. The 
reason for the high number of individuals with the e4 allele in 
this sample is unclear. It could be that persons with a positive 
ApoE e4 status (a vulnerability gene variant) are more sus-
ceptible to multiple disorders, including depression.
Strengths and limitations
The strengths of our study are that it is a case–control 
design where all the patients were from the same county 
and hospital. Furthermore, the control group had many of 
the same symptoms (especially fatigue) as the depressed 
patients, but no affective disorder.
One limitation to this study is the sample size, requiring 
that conclusions must be drawn with caution.
Conclusion
The presence of ApoE e4, which has been associated with 
inflammation, cardiovascular risk factors, and metabolic 
disturbances, was associated with elevated systolic and 
diastolic BP in patients with depression – but not in patients 
with neurological symptoms. The results of this study suggest 
that patients with depression and ApoE e4-positive status are 
particularly prone to develop BP elevation.
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